Video

Dr. Ginsburg Addresses Global Disparities in Cervical Cancer

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, addresses global disparities in cervical cancer.

Until now, many countries have been understandably reluctant to allocating resources toward cancer, as it has historically been seen as an expensive disease to treat, and almost impossible to prevent, says Ginsburg.

There are many opportunities to tackle cervical cancer control in low- and middle-income countries that may not be obvious, says Ginsburg. The first option is to improve the health system for cancer care more broadly, such as teaching the importance of radiotherapy and brachytherapy. It is important to include these technologies, infrastructures, resources, and training in order to address the cancer burden as a whole in these countries. Once that is done, preventing or treating a disease such as cervical cancer, which is relatively well controlled in the first-world, will be an easier task.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD